Latest Biotechnology News

Imagion Biosystems has secured a AU$3 million capital injection and resumed its collaboration with Siemens, setting the stage to prioritize FDA filings and advance its MagSense® HER2 breast cancer imaging program.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.